Flavio Moroni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Flavio Moroni has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Elena Meli
Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50135 Florence, Italy
4 shared publicationsAndrea Cozzi
Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50135 Florence, Italy
3 shared publicationsAlberto Chiarugi
Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50135 Florence, Italy
2 shared publicationsDomenico E Pellegrini-Giampietro
Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50135 Florence, Italy
2 shared publicationsRaffaella Carpenedo
2 shared publicationsA Chiarugi
1 shared publication
Latest Publications
- 4 March 2003
- Published by Elsevier in Toxicology Letters
- Vol. 139 (2-3) , 153-162
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage
- 4 March 2003
- Published by Elsevier in Toxicology Letters
- Vol. 139 (2-3) , 153-162
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage
- 1 January 2003
- Published by Springer Nature
- Vol. 527, 127-136
Studies on the Neuroprotective Action of Kynurenine Mono-Oxygenase Inhibitors in Post-Ischemic Brain Damage
Kynurenine 3-mono-oxygenase (KMO) inhibitors facilitate kynurenic acid (KYNA) neosynthesis and reduce the formation of 30H-kynurenine (3-HK) and quinolinic acid (QUIN). They also attenuate post-ischemic brain damage and decrease glutamate (Glu) content in brain extracellular spaces. To investigate KMO mechanism(s) of neuroprotection, we performed experiments in gerbils subjected to bilateral carotid occlusion and in organotypic rat hippocampal slice cultures exposed to oxygen and glucose deprivation (OGD). In gerbils, direct application of KYNA (100 nM, through reverse microdialysis in the hippocampus) completely prevented the increase in Glu output induced by transient (5 min) occlusion of the carotids. In rat hippocampal slices exposed for 30 min to OGD, KMO inhibitors (mnitrobenzoyl)-alanine (mNBA, 30-100.tM) or 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol2y1]-benzenesulfonamide (Ro 61-8048, 1-10 p.M) reduced post-ischemic neuronal death and increased KYNA concentrations in the incubation medium. KYNA may antagonize glycinesor a7 nicotinic acetylcholine receptors but the concentrations in the incubation medium never reached values that could efficiently antagonize receptor function. On the contrary, 3-HK (1-10 kiM) added to slices exposed to OGD in the presence of KMO inhibitors completely prevented the neuroprotective effects of the inhibitors. Our findings suggest that KMO inhibitors reduce OGD-induced pyramidal cell death by decreasing 3-HK (and possibly QUIN) synthesis.
- 1 January 2003
- Published by Springer Nature
- Vol. 527, 127-136
Studies on the Neuroprotective Action of Kynurenine Mono-Oxygenase Inhibitors in Post-Ischemic Brain Damage
Kynurenine 3-mono-oxygenase (KMO) inhibitors facilitate kynurenic acid (KYNA) neosynthesis and reduce the formation of 30H-kynurenine (3-HK) and quinolinic acid (QUIN). They also attenuate post-ischemic brain damage and decrease glutamate (Glu) content in brain extracellular spaces. To investigate KMO mechanism(s) of neuroprotection, we performed experiments in gerbils subjected to bilateral carotid occlusion and in organotypic rat hippocampal slice cultures exposed to oxygen and glucose deprivation (OGD). In gerbils, direct application of KYNA (100 nM, through reverse microdialysis in the hippocampus) completely prevented the increase in Glu output induced by transient (5 min) occlusion of the carotids. In rat hippocampal slices exposed for 30 min to OGD, KMO inhibitors (mnitrobenzoyl)-alanine (mNBA, 30-100.tM) or 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol2y1]-benzenesulfonamide (Ro 61-8048, 1-10 p.M) reduced post-ischemic neuronal death and increased KYNA concentrations in the incubation medium. KYNA may antagonize glycinesor a7 nicotinic acetylcholine receptors but the concentrations in the incubation medium never reached values that could efficiently antagonize receptor function. On the contrary, 3-HK (1-10 kiM) added to slices exposed to OGD in the presence of KMO inhibitors completely prevented the neuroprotective effects of the inhibitors. Our findings suggest that KMO inhibitors reduce OGD-induced pyramidal cell death by decreasing 3-HK (and possibly QUIN) synthesis.
- 19 September 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 82 (6) , 1465-1471
Kynurenine 3‐mono‐oxygenase inhibitors attenuate post‐ischemic neuronal death in organotypic hippocampal slice cultures
Kynurenine 3‐mono‐oxygenase (KMO) inhibitors reduce 3‐hydroxykynurenine (3‐HK) and quinolinic acid (QUIN) neosynthesis and facilitate kynurenine metabolism towards kynurenic acid (KYNA) formation. They also reduce tissue damage in models of focal or transient global cerebral ischemia in vivo. We used organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation (OGD) to investigate KMO mechanism(s) of neuroprotective activity. Exposure of the slices to 30 min of OGD caused CA1 pyramidal cell death and significantly decreased the amount of KYNA released in the incubation medium. The KMO inhibitors (m‐nitrobenzoyl)‐alanine (30–100 µm) or 3,4‐dimethoxy‐[‐N‐4‐(nitrophenyl)thiazol‐2yl]‐benzenesulfonamide (1–10 µm) reduced post‐ischemic neuronal death and increased KYNA concentrations in slice incubation media. The maximal concentration of KYNA detected in the incubation media of slices treated with KMO inhibitors was approximately 50 nm and was too low to efficiently interact with α7 nicotinic acetylcholine receptors or with the glycineb site of N‐methyl‐d‐aspartate (NMDA) receptors. On the other hand, the addition of either 3‐HK or QUIN (1–10 µm) to OGD‐exposed hippocampal slices prevented the neuroprotective activity of KMO inhibitors. Our results suggest that KMO inhibitors reduce the neuronal death found in the CA1 region of organotypic hippocampal slices exposed to 30 min of OGD by decreasing the local synthesis of 3‐HK and QUIN.
- 19 September 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 82 (6) , 1465-1471
Kynurenine 3‐mono‐oxygenase inhibitors attenuate post‐ischemic neuronal death in organotypic hippocampal slice cultures
Kynurenine 3‐mono‐oxygenase (KMO) inhibitors reduce 3‐hydroxykynurenine (3‐HK) and quinolinic acid (QUIN) neosynthesis and facilitate kynurenine metabolism towards kynurenic acid (KYNA) formation. They also reduce tissue damage in models of focal or transient global cerebral ischemia in vivo. We used organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation (OGD) to investigate KMO mechanism(s) of neuroprotective activity. Exposure of the slices to 30 min of OGD caused CA1 pyramidal cell death and significantly decreased the amount of KYNA released in the incubation medium. The KMO inhibitors (m‐nitrobenzoyl)‐alanine (30–100 µm) or 3,4‐dimethoxy‐[‐N‐4‐(nitrophenyl)thiazol‐2yl]‐benzenesulfonamide (1–10 µm) reduced post‐ischemic neuronal death and increased KYNA concentrations in slice incubation media. The maximal concentration of KYNA detected in the incubation media of slices treated with KMO inhibitors was approximately 50 nm and was too low to efficiently interact with α7 nicotinic acetylcholine receptors or with the glycineb site of N‐methyl‐d‐aspartate (NMDA) receptors. On the other hand, the addition of either 3‐HK or QUIN (1–10 µm) to OGD‐exposed hippocampal slices prevented the neuroprotective activity of KMO inhibitors. Our results suggest that KMO inhibitors reduce the neuronal death found in the CA1 region of organotypic hippocampal slices exposed to 30 min of OGD by decreasing the local synthesis of 3‐HK and QUIN.
- 9 May 2002
- Published by Elsevier in Neuropharmacology
- Vol. 42 (6) , 741-751
The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death
- 9 May 2002
- Published by Elsevier in Neuropharmacology
- Vol. 42 (6) , 741-751
The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death
- 28 August 2001
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 8 (9) , 921-932
Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia
Cell death and differentiation is a monthly research journal focused on the exciting field of programmed cell death and apoptosis. It provides a single accessible source of information for both scientists and clinicians, keeping them up-to-date with advances in the field. It encompasses programmed cell death, cell death induced by toxic agents, differentiation and the interrelation of these with cell proliferation.
- 28 August 2001
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 8 (9) , 921-932
Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia
Cell death and differentiation is a monthly research journal focused on the exciting field of programmed cell death and apoptosis. It provides a single accessible source of information for both scientists and clinicians, keeping them up-to-date with advances in the field. It encompasses programmed cell death, cell death induced by toxic agents, differentiation and the interrelation of these with cell proliferation.